Kura Oncology (KURA) Liabilities and Shareholders Equity (2010 - 2026)

Kura Oncology (KURA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $652.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $652.6 million, down 12.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 9.0% YoY), and the FY2025 annual result was $738.4 million, down 2.87% from the prior year.
• Liabilities and Shareholders Equity fell to $652.6 million in Q1 2026 per KURA's latest filing, from $738.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $760.2 million in Q4 2024 and troughed at $426.0 million in Q1 2023.
• A 5-year average of $558.4 million and a median of $498.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity declined 20.16% in 2022, then soared 69.32% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $456.3 million in 2022, then dropped by 1.62% to $448.9 million in 2023, then surged by 69.32% to $760.2 million in 2024, then declined by 2.87% to $738.4 million in 2025, then dropped by 11.62% to $652.6 million in 2026.
• Business Quant data shows KURA's Liabilities and Shareholders Equity at $652.6 million in Q1 2026, $738.4 million in Q4 2025, and $649.4 million in Q3 2025.